No association between HPV vaccination and risky sexual behaviors found in girls
the ONA take:
A significant concern in regard to young girls receiving the human papillomavirus (HPV) vaccine was that introducing the idea of sexual activity at a young age would increase the risk of those girls’ engaging in risky sexual behaviors.
Researchers at Harvard Medical School and the University of Southern California investigated the concept. Their findings suggest that the vaccine does not promote risky sexual behaviors among those who received it. The study included 21,000 girls who received the vaccination matched with 186,000 girls who did not receive it.
Both groups were the same age, had the same insurance plan, and lived in the same geographic area of the United States. The researchers measured rates of sexually transmitted infections (STIs) quarterly for 1 year before and 1 year after vaccination.
Although rates of STIs was slightly higher among the vaccinated girls before and after vaccination, the rate of STIs increased at the same pace in both groups. The researchers conclude that if receipt of the HPV vaccine caused an increase in risky sexual behavior, they would have seen a steeper increase in STIs among the vaccinated girls.
This did not occur, which lead to their conclusion that receipt of the HPV vaccine was not associated with unsafe sexual practices. Two HPV vaccines are currently available, Ceravix and Gardasil.
Both prevent cervical cancer; Gardasil also protects against genital warts and anal cancer in both girls and boys, and against vulvar cancer and vaginal cancer in girls. HPV vaccination is recommended for preteen girls and boys at age 11 or 12 years.
Gardasil protects against genital warts and anal cancer in both girls and boys, and against vulvar cancer and vaginal cancer in girls.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|